Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial.

@article{Strober2012SleepQA,
  title={Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial.},
  author={B E Strober and Jeffrey M. Sobell and Kristina Callis Duffin and Yanjun Bao and Annie Gu{\'e}rin and H Yang and Orin M. Goldblum and Martin M Okun and Parvez M. Mulani},
  journal={The British journal of dermatology},
  year={2012},
  volume={167 6},
  pages={1374-81}
}
BACKGROUND Psoriasis is associated with poor health-related quality of life, including sleep impairment. OBJECTIVE To assess the extent of sleep impairment, the effect of adalimumab on sleep and other patient-reported outcomes, and correlations between changes in these outcomes and sleep quality in patients with psoriasis. METHODS Patients in the 16-week, open-label, Phase IIIb PROGRESS trial had chronic plaque psoriasis and suboptimal response to prior therapy (etanercept, methotrexate or… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 38 references

HUMIRA. Prescribing Information

  • Abbott Laboratories
  • Abbott Laboratories,
  • 2011
1 Excerpt

Similar Papers

Loading similar papers…